Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 18/20 | 0.91 |
| ▸ | RAB9A | P51151 | 17/20 | 0.91 |
| ▸ | MEN1 | O00255 | 13/20 | 0.91 |
| ▸ | KMT2A | Q03164 | 13/20 | 0.91 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.88 |
| ▸ | MAPT | P10636 | 7/20 | 0.88 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.88 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.88 |
| ▸ | RELA | Q04206 | 4/20 | 0.88 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.88 |
| ▸ | TP53 | P04637 | 3/20 | 0.88 |
| ▸ | LMNA | P02545 | 2/20 | 0.88 |
| ▸ | HTT | P42858 | 1/20 | 0.80 |
| ▸ | MECP2 | P51608 | 1/20 | 0.77 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.77 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.77 |
| ▸ | MBD2 | Q9UBB5 | 1/20 | 0.77 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.77 |
| ▸ | GAA | P10253 | 3/20 | 0.77 |
| ▸ | ALPL | P05186 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL7669000 | 0.98 | NPC1 (0.88) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18029575 | 0.95 | NPC1 (0.94) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL29427807 | 0.95 | NPC1 (0.94) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16217145 | 0.95 | NPC1 (1.00) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18029541 | 0.94 | NPC1 (0.94) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL29427808 | 0.94 | NPC1 (0.94) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12296219 | 0.94 | NPC1 (1.00) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL24624830 | 0.93 | NPC1 (0.79) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18029570 | 0.93 | NPC1 (0.79) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18029509 | 0.93 | NPC1 (0.79) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9974795-B2 | Anticancer agent composition | CARNA BIOSCIENCES, INC. (JP) | 2018-05-22 | — | — | US | claimed |
| US-20170065609-A1 | ANTICANCER AGENT COMPOSITION | CARNA BIOSCIENCES, INC. (JP) | 2017-03-09 | — | — | US | claimed |
| EP-3100742-A1 | ANTICANCER AGENT COMPOSITION | Carna Biosciences Inc. (JP) | 2016-12-07 | — | — | EP | claimed |
| US-6448272-B1 | SUCH AS 1,4-BIS(2-PHENYLAMINO-4-THIAZOLYL)BENZENE; CANCER AND HYPERPROLIFERATIVE DISEASES. | SMITHKLINE BEECHAM CORPORATION | 2002-09-10 | — | — | US | claimed |
| EP-1146875-A4 | MYT1 KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-05-02 | — | — | EP | claimed |
| EP-1146875-A1 | MYT1 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-24 | — | — | EP | claimed |
| WO-2000033841-A1 | MYT1 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-06-15 | — | — | WO | claimed |
| EP-3100742-B1 | ANTICANCER AGENT COMPOSITION COMPRISING A CDC7 INHIBITOR AND A WEE1 INHIBITOR | CARNA BIOSCIENCES INC (JP) | 2020-05-20 | — | — | EP | disclosed |
| US-9974795-B2 | Anticancer agent composition | CARNA BIOSCIENCES, INC. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-20170065609-A1 | ANTICANCER AGENT COMPOSITION | CARNA BIOSCIENCES, INC. (JP) | 2017-03-09 | — | — | US | disclosed |
| EP-3100742-A1 | ANTICANCER AGENT COMPOSITION | Carna Biosciences Inc. (JP) | 2016-12-07 | — | — | EP | disclosed |
| US-6448272-B1 | SUCH AS 1,4-BIS(2-PHENYLAMINO-4-THIAZOLYL)BENZENE; CANCER AND HYPERPROLIFERATIVE DISEASES. | SMITHKLINE BEECHAM CORPORATION | 2002-09-10 | — | — | US | disclosed |
| EP-1146875-A4 | MYT1 KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-05-02 | — | — | EP | disclosed |
| EP-1146875-A1 | MYT1 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000033841-A1 | MYT1 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170065609-A1 | ANTICANCER AGENT COMPOSITION | CDC7, CDC16, MCM7 | NPC1 1997/4885RAB9A 3325/4885MEN1 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.